Alan Stenback, Author at Amidebio

AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical Development of its Long- Acting Stable Glucagon Analog for the Treatment of Hyperinsulinism

In News by Alan StenbackOctober 4, 2022

BOULDER, CO, October 4th, 2022 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $2.69M in funding through a Phase IIB Small Business Innovation Research …